These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 2574842

  • 1. [Liver-protective action of silymarin therapy in chronic alcoholic liver diseases].
    Fehér J, Deák G, Müzes G, Láng I, Niederland V, Nékám K, Kárteszi M.
    Orv Hetil; 1989 Dec 17; 130(51):2723-7. PubMed ID: 2574842
    [Abstract] [Full Text] [Related]

  • 2. [Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases].
    Deák G, Müzes G, Láng I, Niederland V, Nékám K, Gonzalez-Cabello R, Gergely P, Fehér J.
    Orv Hetil; 1990 Jun 17; 131(24):1291-2, 1295-6. PubMed ID: 2195425
    [Abstract] [Full Text] [Related]

  • 3. [Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol)].
    Müzes G, Deák G, Láng I, Nékám K, Niederland V, Fehér J.
    Orv Hetil; 1990 Apr 22; 131(16):863-6. PubMed ID: 2345633
    [Abstract] [Full Text] [Related]

  • 4. Hepatoprotective and immunomodulatory effects of antioxidant therapy.
    Láng I, Deák G, Nékám K, Müzes G, González-Cabello R, Gergely P, Fehér J.
    Acta Med Hung; 1988 Apr 22; 45(3-4):287-95. PubMed ID: 3074277
    [Abstract] [Full Text] [Related]

  • 5. [Controlled study of the effect of silymarin on alcoholic liver disease].
    Bunout D, Hirsch S, Petermann M, de la Maza MP, Silva G, Kelly M, Ugarte G, Iturriaga H.
    Rev Med Chil; 1992 Dec 22; 120(12):1370-5. PubMed ID: 1343377
    [Abstract] [Full Text] [Related]

  • 6. Hepatoprotective and immunological effects of antioxidant drugs.
    Láng I, Nékám K, González-Cabello R, Mũzes G, Gergely P, Fehér J.
    Tokai J Exp Clin Med; 1990 May 22; 15(2-3):123-7. PubMed ID: 1983370
    [Abstract] [Full Text] [Related]

  • 7. [Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C].
    Pár A, Róth E, Rumi G, Kovács Z, Nemes J, Mózsik G.
    Orv Hetil; 2000 Jul 23; 141(30):1655-9. PubMed ID: 10962902
    [Abstract] [Full Text] [Related]

  • 8. Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers.
    Láng I, Nékám K, Deák G, Müzes G, Gonzales-Cabello R, Gergely P, Csomós G, Fehér J.
    Ital J Gastroenterol; 1990 Oct 23; 22(5):283-7. PubMed ID: 1983711
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Short term treatment of type II hyperlipoproteinaemia with silymarin.
    Somogyi A, Ecsedi GG, Blázovics A, Miskolczi K, Gergely P, Fehér J.
    Acta Med Hung; 1989 Oct 23; 46(4):289-95. PubMed ID: 2699920
    [Abstract] [Full Text] [Related]

  • 11. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z.
    Fundam Clin Pharmacol; 2009 Jun 23; 23(3):359-65. PubMed ID: 19453758
    [Abstract] [Full Text] [Related]

  • 12. [The influence of therapy with silymarin on the survival rate of patients with liver cirrhosis (author's transl)].
    Benda L, Dittrich H, Ferenzi P, Frank H, Wewalka F.
    Wien Klin Wochenschr; 1980 Oct 10; 92(19):678-83. PubMed ID: 7008367
    [Abstract] [Full Text] [Related]

  • 13. [Silymarin treatment of alcoholic liver disease].
    Orv Hetil; 1990 Jul 22; 131(29):1607-9. PubMed ID: 2392321
    [No Abstract] [Full Text] [Related]

  • 14. Clinical, enzymological and histological changes in chronic diffuse liver diseases following (+)-cyanidanol-3 (Catergen) treatment.
    Halmy L, Dávid K, Nagy I, Stotz G, Kelemen JT.
    Acta Physiol Hung; 1984 Jul 22; 64(3-4):461-70. PubMed ID: 6152370
    [Abstract] [Full Text] [Related]

  • 15. (+)-Cyanidanol-3 for alcoholic liver disease: results of a six-month clinical trial.
    World MJ, Aps EJ, Shaw GK, Thomson AD.
    Alcohol Alcohol; 1984 Jul 22; 19(1):23-9. PubMed ID: 6149758
    [Abstract] [Full Text] [Related]

  • 16. Use of the Romanian product Silimarina in the treatment of chronic liver diseases.
    Tănăsescu C, Petrea S, Băldescu R, Macarie E, Chiriloiu C, Purice S.
    Med Interne; 1988 Jul 22; 26(4):311-22. PubMed ID: 3072661
    [Abstract] [Full Text] [Related]

  • 17. Affect of silymarin on serum levels of ALT and GGT in ethanol induced hepatotoxicity in albino rats.
    Habib-ur-Rehman M, Mahmood T, Salim T, Afzal N, Ali N, Iqbal J, Tahir M, Khan A.
    J Ayub Med Coll Abbottabad; 2009 Jul 22; 21(4):73-5. PubMed ID: 21067030
    [Abstract] [Full Text] [Related]

  • 18. [Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres (author's transl)].
    Magliulo E, Gagliardi B, Fiori GP.
    Med Klin; 1978 Jul 14; 73(28-29):1060-5. PubMed ID: 353464
    [Abstract] [Full Text] [Related]

  • 19. [Silymarin for the treatment of acute viral hepatitis? Report of a controlled trial (author's transl)].
    Bode JC, Schmidt U, Dürr HK.
    Med Klin; 1977 Mar 25; 72(12):513-8. PubMed ID: 840125
    [Abstract] [Full Text] [Related]

  • 20. [Therapy of acute virus hepatitis with silymarin. Report of a controlled study].
    Schmidt U, Dürr HK, Bode JC.
    Verh Dtsch Ges Inn Med; 1977 Mar 25; 83():563-5. PubMed ID: 25535
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.